Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine (Nasdaq: CMND) has announced the publication of a patent by Mexico's National Patent Office (IMPI) for its combination therapy treatment. The patent covers an innovative treatment combining MEAI and N-Acylethanolamines, targeting various binge behaviors including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent emerged from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on developing treatments for central nervous system disorders. The partnership aims to research combination therapies that integrate psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company developing psychedelic-derived therapeutics, announced the successful approval of all matters presented at its January 6, 2025 shareholders meeting. Key approvals include:
- Setting the board of directors at five members
- Election of directors for the upcoming year
- Appointment of Brightman Almagor Zohar & Co. (Deloitte Global Network) as company auditor
- Establishment of an omnibus equity incentive plan
- Authorization for potential share consolidation up to 50:1 ratio at board's discretion
Clearmind Medicine (Nasdaq: CMND) announced the publication of a European patent application for its combination therapy using MEAI and N-Acylethanolamines. The therapy targets various binge behaviors, including alcohol, eating, tobacco, shopping, and sexual conduct.
The patent stems from Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on combining psychedelic compounds with N-Acylethanolamines family, including Palmitoylethanolamide (PEA). The company has filed 13 patents across multiple jurisdictions related to this collaboration, strengthening its intellectual property portfolio in psychedelic therapies for binge behavior treatment.
Clearmind Medicine (NASDAQ: CMND) has received patent approval from the Macau International Intellectual Property Office for its MEAI-based binge behavior regulator program. The patent covers primary amine aminoindan compounds, including but not to 5-methoxy-2-aminoindan (MEAI), for regulating binge behavior.
This addition to Clearmind's intellectual property portfolio brings their total to 31 granted patents across 18 patent families, with coverage in major jurisdictions including the US, Europe, China, India, Hong Kong, and Macau. The company focuses on developing non-hallucinogenic proprietary molecules for treating substance addictions related to alcohol and food.
Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using Dr Glitter's ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.
The ActivCrystal™ format consists of tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Users will be able to adjust dosage individually by sprinkling the MEAI-based alternative into beverages or food. This partnership represents a strategic move in Clearmind's efforts to bring MEAI to global markets as a solution to combat alcohol misuse.
Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be conducted at Yale School of Medicine's Department of Psychiatry under Dr. Anahita Bassir Nia's leadership. This FDA-regulated clinical program aims to evaluate the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD.
The development addresses a significant global health issue, as alcohol consumption causes 2.6 million deaths annually worldwide and represents 4.7% of global deaths. Current AUD treatments face challenges including high costs, low efficacy (less than 30%), and poor patient compliance due to side effects.
Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr. Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.
The ActivCrystal™ technology encapsulates active ingredients in tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Upon finalizing a definitive agreement, the product will allow users to add MEAI-based crystals to their choice of beverage or food with adjustable dosage.
This partnership represents a strategic move in Clearmind's efforts to introduce MEAI to global markets as a solution to combat alcohol misuse.
Clearmind Medicine Inc. (Nasdaq: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a MEAI-based treatment for alcohol use disorder (AUD). This approval marks the second clinical site for the multinational, multi-center trial, which will assess the safety, tolerability, and pharmacokinetics of CMND-100.
The trial will take place at Johns Hopkins University, Yale School of Medicine, and IMCA Center in Israel. Clearmind has already secured FDA approval for its Investigational New Drug (IND) application in the U.S. and approval from the Israeli Ministry of Health.
The primary endpoint of the trial is to determine the tolerable dose and evaluate the safety, pharmacokinetics, and pharmacodynamics of CMND-100. This milestone brings Clearmind closer to offering a potential solution for AUD, which is a major global health issue and the most common substance use disorder among people aged 12 and older in the U.S.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a pioneering combination therapy of Ibogaine and N-Acylethanolamines. This innovative treatment, developed in collaboration with SciSparc (Nasdaq: SPRC), aims to enhance safety and efficacy in mental health and addiction care.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown promise in treating various substance use disorders. The combination with N-Acylethanolamines, including Palmitoylethanolamide (PEA), is expected to further improve the therapy's effectiveness and safety profile. This development underscores Clearmind's commitment to leadership in the psychedelics space and its focus on providing safe solutions for unmet mental health needs.
Clearmind Medicine Inc. (Nasdaq: CMND) has filed an international patent application for innovative psychedelic compounds designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions. This application is part of Clearmind's collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The compounds were invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel.
The global PTSD treatment market, valued at $16.8 billion in 2023, is projected to reach $27.37 billion by 2033. Current PTSD treatments offer efficacy, and FDA-approved drugs often come with side effects. Clearmind aims to develop effective and safe next-generation psychedelic compounds to significantly improve patients' quality of life.